Member Info for Basser1

Sierra currently only have two assets in its pipeline, Momelotinib and SRA737. It has submitted two Trademark applications both in the same classification ie Cancers and Immunotherapy ( plus some other areas). Make of it what you will. We are just waiting for further news from Sierra.

You do want the shares badly don’t you. Keep it up, you can almost feel the desperation.

Workingpharma - agree with what you say but at the moment would question your view of a drop to 1.8. As far as I am aware we have never had consistent block buying like we have now. It might drop but only when the block buying stops or we get some bad news.

For information.
https://uspto.report/TM/90461173
https://uspto.report/TM/90461170

Agree Belhus. Sierra has two assets in its pipeline, Momelotinib and SRA 737. The trademarks are a vital part of the process of branding to safeguard commercial interests.

Morning Potnak
I take your point that all the inhibitors have nib in their name but Trademarks are about branding. So for instance Olaparib is branded as Lynporza and Niraparib is branded as Zejula. What we need to find out is what products the two trademark applications made by Sierra are for.

No problem. Assuming one I for Momelotinib and the other for SRA737.

Here is the detail

https://uspto.report/TM/90461173
https://uspto.report/TM/90461170

Sierra submitted the two Trademarks on 12 January 2021 for RYSURJJA and ACUJJERA and the applications were formally accepted today. Both have the same description of what is covered - the treatment of Cancer and Tumor’s, treatment of blood diseases and disorders, bone and bone marrow disease and cancers associated with blood disease. Biological and Chemical preparations for the treatment of Cancers. Pharmaceutical products for the prevention and treatment of cancer and tumors, treatment of blood diseases and disorders.
Very surprised if these do not relate to SRA737 but welcome views on why they would submit two applications with the same description of use.
More evidence that SRA 737 Progress is starting to gather a head of steam.

Just out of interest, was the 2,000,000 trade at 10.40.28 a buy.?

Another nice find citizen. The in Vitro fertilisation market size is projected to be worth USD 31.97 Billion by 2027! And CHK1 (SRA 737) could have a role in this area.
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi0nJ7OxZ3uAhUAQEEAHXW6ASwQFjABegQIBhAC&url=https%3A%2F%2Fwww.prnewswire.co.uk%2Fnews-releases%2Fin-vitro-fertilization-market-size-worth-usd-31-97-billion-by-2027-cagr-of-9-1-emergen-research-845804234.html&usg=AOvVaw01iCHXYzMujlNaehyO3btJ

PGA - quote Warren Buffet “ The market is a device for transferring money from the impatient to the patient”.

???!. Bigtimer- you need to do more homework.

Not new, but Liked this scientific report done by The Institute of Cancer Research (ICR)

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjT-5zvpJnuAhVioVwKHdd3BzYQFjABegQIBBAC&url=https%3A%2F%2Fwww.icr.ac.uk%2Fnews-archive%2Ftwo-pronged-attack-on-dna-repair-could-kill-drug-resistant-cancers&usg=AOvVaw1MZU9_5TDapkzuS8b0BRP1

Glover must have told the institutions a great story! I think I have a good idea of what it was. As RMM said it looks like Dilley has finally got round to developing a plan for SRA 737.GLA

No luck in finding who the big purchaser is. But it is clear that Sierra Oncology continues to have a high percentage of Institutional investors.Fintel puts Institutional Shares at 62.93% of total company shares. CNN Business quote when the institutional holding was much lower, at 36.65% quoted “ This is a greater percentage than is typical for companies in the Biotech Industry and highlights that the Smart money sees Sierra as an important holding”.

All should be revealed today on the identity of the $7,296,250 Sierra share purchase yesterday.

Today - Should be able to find out the buyer that made the $7,296,250 Sierra Share purchase yesterday.

Gone to 2.30?

The timing of the share purchase in tandem with the conference presentation was deliberate in my opinion. It distances the purchase from being linked to momentum. Won.’t be to long now before all is revealed.